Logo image of MAK.DE

MATERNUS-KLINIKEN AG (MAK.DE) Stock Fundamental Analysis

FRA:MAK - Deutsche Boerse Ag - DE0006044001 - Common Stock - Currency: EUR

1.73  -0.02 (-1.14%)

Fundamental Rating

1

Overall MAK gets a fundamental rating of 1 out of 10. We evaluated MAK against 25 industry peers in the Health Care Providers & Services industry. Both the profitability and financial health of MAK have multiple concerns. MAK has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year MAK has reported negative net income.
MAK had a positive operating cash flow in the past year.
In the past 5 years MAK always reported negative net income.
MAK had a positive operating cash flow in each of the past 5 years.
MAK.DE Yearly Net Income VS EBIT VS OCF VS FCFMAK.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 10M -10M

1.2 Ratios

The Return On Assets of MAK (-9.47%) is worse than 91.67% of its industry peers.
Industry RankSector Rank
ROA -9.47%
ROE N/A
ROIC N/A
ROA(3y)-6.64%
ROA(5y)-6.3%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MAK.DE Yearly ROA, ROE, ROICMAK.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20 -20 40 -40 60 -60

1.3 Margins

With an excellent Gross Margin value of 85.47%, MAK belongs to the best of the industry, outperforming 87.50% of the companies in the same industry.
MAK's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for MAK so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 85.47%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0%
GM growth 5Y0.65%
MAK.DE Yearly Profit, Operating, Gross MarginsMAK.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20 40 60 80

More info and screens

1

2. Health

2.1 Basic Checks

MAK does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for MAK remains at a similar level compared to 1 year ago.
MAK has about the same amout of shares outstanding than it did 5 years ago.
MAK has a better debt/assets ratio than last year.
MAK.DE Yearly Shares OutstandingMAK.DE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M
MAK.DE Yearly Total Debt VS Total AssetsMAK.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M

2.2 Solvency

Based on the Altman-Z score of -0.80, we must say that MAK is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of MAK (-0.80) is worse than 87.50% of its industry peers.
MAK has a debt to FCF ratio of 14.20. This is a negative value and a sign of low solvency as MAK would need 14.20 years to pay back of all of its debts.
MAK has a Debt to FCF ratio of 14.20. This is in the lower half of the industry: MAK underperforms 75.00% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 14.2
Altman-Z -0.8
ROIC/WACCN/A
WACC5.13%
MAK.DE Yearly LT Debt VS Equity VS FCFMAK.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M 100M

2.3 Liquidity

MAK has a Current Ratio of 0.29. This is a bad value and indicates that MAK is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 0.29, MAK is doing worse than 95.83% of the companies in the same industry.
MAK has a Quick Ratio of 0.29. This is a bad value and indicates that MAK is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of MAK (0.28) is worse than 91.67% of its industry peers.
Industry RankSector Rank
Current Ratio 0.29
Quick Ratio 0.28
MAK.DE Yearly Current Assets VS Current LiabilitesMAK.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for MAK have decreased by -1.28% in the last year.
The Revenue has decreased by -4.12% in the past year.
Measured over the past years, MAK shows a decrease in Revenue. The Revenue has been decreasing by -3.82% on average per year.
EPS 1Y (TTM)-1.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%43.75%
Revenue 1Y (TTM)-4.12%
Revenue growth 3Y-3.63%
Revenue growth 5Y-3.82%
Sales Q2Q%124.88%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MAK.DE Yearly Revenue VS EstimatesMAK.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M
MAK.DE Yearly EPS VS EstimatesMAK.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 -0.02 -0.04 -0.06

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MAK. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MAK.DE Price Earnings VS Forward Price EarningsMAK.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

83.33% of the companies in the same industry are cheaper than MAK, based on the Enterprise Value to EBITDA ratio.
83.33% of the companies in the same industry are more expensive than MAK, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 2.76
EV/EBITDA 43.5
MAK.DE Per share dataMAK.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for MAK!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MATERNUS-KLINIKEN AG

FRA:MAK (2/4/2025, 7:00:00 PM)

1.73

-0.02 (-1.14%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)09-02 2024-09-02
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners81.7%
Ins Owner ChangeN/A
Market Cap36.28M
Analysts45.71
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.35
P/FCF 2.76
P/OCF 1.94
P/B N/A
P/tB N/A
EV/EBITDA 43.5
EPS(TTM)-0.68
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0.63
FCFY36.21%
OCF(TTM)0.89
OCFY51.41%
SpS4.88
BVpS-2.65
TBVpS-3.28
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -9.47%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 85.47%
FCFM 12.84%
ROA(3y)-6.64%
ROA(5y)-6.3%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0%
GM growth 5Y0.65%
F-Score3
Asset Turnover0.68
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 14.2
Debt/EBITDA 26.69
Cap/Depr 54.86%
Cap/Sales 5.39%
Interest Coverage N/A
Cash Conversion 391.6%
Profit Quality N/A
Current Ratio 0.29
Quick Ratio 0.28
Altman-Z -0.8
F-Score3
WACC5.13%
ROIC/WACCN/A
Cap/Depr(3y)25.39%
Cap/Depr(5y)18.15%
Cap/Sales(3y)2.49%
Cap/Sales(5y)1.78%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%43.75%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-4.12%
Revenue growth 3Y-3.63%
Revenue growth 5Y-3.82%
Sales Q2Q%124.88%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y43.4%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y55.85%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y77.47%
OCF growth 3Y-40.8%
OCF growth 5Y-16.54%